Beddok A, Bouazzi L, Barbe C, Martin P, Gratiaux J, Guilbert P, Job L, Lemoine A, Morland D, Papathanassiou D, Perin S, Merrouche Y, Nifosi G, Soibinet P, Vignot S, Hotton J

J Cancer Educ. 2025 01 27;:

[In times of uncertainty…].

Vignot S, l'Allemain G, Pourquier P, Bay JO,

Bull Cancer. 2025 01;112(1):1-3

[Evaluating patient experience in oncology and chronic diseases: Critical analysis of available tools (PROMs, PREMs, Satisfaction)].

Diouri L, Barbe C, Vignot S

Bull Cancer. 2024 12 30;:

[A 2024 inventory in oncology news].

Vignot S, Bellesoeur A, Bouleuc C, Cohen R, Courtier B, De Nonneville A, Delom F, Evrard S, Firmin N, Gandemer V, Khettab M, Magné N, Orbach D, Pellier I, Rodrigues M, Wislez M, Bay JO

Bull Cancer. 2024 12 16;:

[Selpercatinib in advanced solid tumors with RET fusion, in the absence of therapeutic alternatives].

Helal C, Vignot S

Bull Cancer. 2024 12 9;:

Prise en charge des cancers thyroïdiens en 2024 : un numéro spécial exemplaire

Vignot S, Bay JO

Bull Cancer. 2024 10;111(10S1):10S1-10S2

[Drosophila: When you've got us!].

Bay JO, Vignot S

Bull Cancer. 2024 09;111(9):791-792

Enhanced expression of galectin-9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy.

Lerévérend C, Kotaich N, Cartier L, De Boni M, Lahire S, Fichel C, Thiebault C, Brabencova E, Maquin C, Barbosa E, Corsois L, Hotton J, Guendouzen S, Guilbert P, Lepagnol-Bestel AM, Cahen-Doidy L, Lehmann-Che J, Devy J, Bensussan A, Le Jan S, Pommier A, Merrouche Y, Le Naour R, Vignot S, Potteaux S

Int J Cancer. 2024 07 30;:

[Balancing drug regulation and health democracy: The role of patient and healthcare professional advisors at the ANSM].

Maison P, Bacon T, Daynes P, Decoene C, Mazet R, Vial T, Vignot S, Belgodère L, Oualikene-Gonin W, Ratignier-Carbonneil C

Therapie. 2024 06 22;:

Prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.

Invernizzi C, Da Silva Ribeiro Mota A, Barbe C, Bouazzi L, Marques O, Munschi L, Marchand-Crety C, Jacquin N, Dubernard X, Beddok A, Lasset C, Assouly N, Vignot S, Brenet E

Oral Oncol. 2024 05 9;153:106833

[News, when you hold us…].

Bay JO, l'Allemain G, Pourquier P, Vignot S

Bull Cancer. 2024 02;111(2):127-128

[From 2023 to 2024: Consolidate our achievements, stay on course for innovation and progress].

Vignot S, Pourquier P, l'Allemain G, Bay JO,

Bull Cancer. 2024 01;111(1):1-2

Prevention and management of health products shortages by the French national agency (ANSM), 10 years of experience.

Belgodère L, Emmerich J, Albin N, Bacon T, Daynes P, Vignot S, Vial T, Renaud G, Le Saulnier C, Maillard-Couvreur C, Cachet M, Veyries ML, Youdarene R, Oualikene-Gonin W, Ratignier-Carbonneil C, Maison P

Front Public Health. 2023 11 17;11:1293110

Biomarkers of response to immunotherapy in early stage non-small cell lung cancer.

Roulleaux Dugage M, Albarrán-Artahona V, Laguna JC, Chaput N, Vignot S, Besse B, Mezquita L, Auclin E

Eur J Cancer. 2023 05;184:179-196

Clinical Trial Authorisation: A Final Look Back to Better Appraise the New European Regulation.

Vignot S, Guyader G, Salomon V, Vella P, Yoldjian I, Maison P, Ratignier-Carbonneil C

Rev Recent Clin Trials. 2023 ;18(3):167-171

Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 study.

Debien V, Vignot S, Massard C, Malouf G, Hollebecque A, Scoazec JY, Michiels S, Verlingue L

Crit Rev Oncol Hematol. 2022 11 29;181:103888

Authorization of COVID-19 clinical trials: lessons from 2 years of experience of a national competent authority.

Vignot S, Dhanani A, Sainte-Marie I, de Ligniville Lajavardi L, Even G, Echemann M, Hulin N, Ménoret C, Maison P, Ratignier-Carbonneil C

Front Pharmacol. 2022 08 15;13:972660

Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer.

Guyot D'Asnières De Salins A, Tachon G, Cohen R, Karayan-Tapon L, Junca A, Frouin E, Godet J, Evrard C, Randrian V, Duval A, Svrcek M, Lascols O, Vignot S, Coulet F, André T, Fléjou JF, Cervera P, Tougeron D

ESMO Open. 2021 06;6(3):100120

Collaboration Between Health-Care Professionals, Patients, and National Competent Authorities Is Crucial for Prevention of Health Risks Linked to the Inappropriate Use of Drugs: A Position Paper of the ANSM (Agence Nationale de Sécurité du Médicament et d

Vignot S, Daynes P, Bacon T, Vial T, Montagne O, Albin N, Emmerich J, Ratignier-Carbonneil C, Martin D, Maison P

Front Pharmacol. 2021 04 28;12:635841

[Clinical trials during pandemic crisis: How to ensure safety and maintain access to innovation].

Vignot S, Le Blaye O, Fluckiger L, Errard S, Marin B, Chapel E

Bull Cancer. 2020 06;107(6):617-619

[New prescription modalities for nominative premarket access: Tailored for infectiology].

Vignot S, Blaise T, Martin M

Med Mal Infect. 2020 06;50(4):386-387

New modalities of prescription of ATUns: Evolutions and revolution.

Vignot S, Plaine G, Chapel E

Rev Neurol (Paris). 2020 05;176(4):290-292

Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety.

Vignot S, Martin M, Albin N, Schurtz C, Chapel E

Ann Oncol. 2019 11 1;30(11):1694-1696

[New prescription procedures for authorisations for temporary use: A key step for access to innovation].

Vignot S, Chapel E

Bull Cancer. 2019 11;106(11):943-945

[Hot topics about early clinical trials at ASCO congress 2018: News pathways, new targets, new associations].

Auvray M, Baylot C, Blanc-Durand F, Borcoman E, Pons-Tostivint E, Vignot S

Bull Cancer. 2018 11;105(11):1084-1093

[Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].

Kfoury M, Disdero V, Vicier C, Le Saux O, Gougis P, Sajous C, Vignot S

Bull Cancer. 2018 06 20;105(7-8):686-695

[Radiation therapy in inflammatory breast cancer].

Jardel P, Alami Z, Vignot S, Creisson A, Danhier S, Geffrelot J, Levy C, Kammerer E, Lebrun JF, Thariat J

Bull Cancer. 2018 04;105(4):415-425

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.

Sun JX, He Y, Sanford E, Montesion M, Frampton GM, Vignot S, Soria JC, Ross JS, Miller VA, Stephens PJ, Lipson D, Yelensky R

PLoS Comput Biol. 2018 02;14(2):e1005965

[HBV infection: Screening and treatment for oncology patients].

Jaillais A, Herber-Mayne A, D'Alteroche L, Landau A, Merrouche Y, Vignot S

Bull Cancer. 2018 Feb;105(2):162-170

[Virus and cancer: Still hot topic].

L'Allemain G, Bay JO, Dutreix M, Vignot S

Bull Cancer. 2018 02;105(2):133-134

Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review.

Jardel P, Vignot S, Cutuli B, Creisson A, Vass S, Barranger E, Thariat J

Anticancer Res. 2018 01;38(1):23-31

[Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer].

Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L'Allemain G, Bay JO

Bull Cancer. 2018 01;105(1):6-14